Tengion is a clinical-stage regenerative medicine company discovering and developing regenerative products. The company’s most advanced product candidate, the Neo-Urinary Conduit™, is currently being evaluated in a phase 1 clinical trial in bladder cancer patients requiring a urinary diversion following cystectomy. TNGN’s lead preclinical candidate, Neo-Kidney Augment™, is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. For more information, visit the company’s Web site: http://www.tengion.com
Let us hear your thoughts below: